Division of Vascular Surgery and Endovascular Therapy, The Johns Hopkins Medical Institutions, Baltimore, MD.
Johns Hopkins Surgery Center for Outcomes Research, Johns Hopkins University School of Medicine, Baltimore, MD.
J Vasc Surg. 2023 Jun;77(6):1720-1731.e3. doi: 10.1016/j.jvs.2023.04.023.
Despite societal guidelines that peripheral vascular intervention (PVI) should not be the first-line therapy for intermittent claudication, a significant number of patients will undergo PVI for claudication within 6 months of diagnosis. The aim of the present study was to investigate the association of early PVI for claudication with subsequent interventions.
We evaluated 100% of Medicare fee-for-service claims to identify all beneficiaries with a new diagnosis of claudication from January 1, 2015 to December 31, 2017. The primary outcome was late intervention, defined as any femoropopliteal PVI performed >6 months after the claudication diagnosis (through June 30, 2021). Kaplan-Meier curves were used to compare the cumulative incidence of late PVI for claudication patients with early (≤6 months) PVI vs those without early PVI. A hierarchical Cox proportional hazards model was used to evaluate the patient- and physician-level characteristics associated with late PVIs.
A total of 187,442 patients had a new diagnosis of claudication during the study period, of whom 6069 (3.2%) had undergone early PVI. After a median follow-up of 4.39 years (interquartile range, 3.62-5.17 years), 22.5% of the early PVI patients had undergone late PVI vs 3.6% of those without early PVI (P < .001). Patients treated by high use physicians of early PVI (≥2 standard deviations; physician outliers) were more likely to have received late PVI than were patients treated by standard use physician of early PVI (9.8% vs 3.9%; P < .001). Patients who had undergone early PVI (16.4% vs 7.8%) and patients treated by outlier physicians (9.7% vs 8.0%) were more likely to have developed CLTI (P < .001 for both). After adjustment, the patient factors associated with late PVI included receipt of early PVI (adjusted hazard ratio [aHR], 6.89; 95% confidence interval [CI], 6.42-7.40) and Black race (vs White; aHR, 1.19; 95% CI, 1.10-1.30). The only physician factor associated with late PVI was a majority of practice in an ambulatory surgery center or office-based laboratory, with an increasing proportion of ambulatory surgery center or office-based laboratory services associated with significantly increased rates of late PVI (quartile 4 vs quartile 1; aHR, 1.57; 95% CI, 1.41-1.75).
Early PVI after the diagnosis of claudication was associated with higher late PVI rates compared with early nonoperative management. High use physicians of early PVI for claudication performed more late PVIs than did their peers, especially those primarily delivering care in high reimbursement settings. The appropriateness of early PVI for claudication needs critical evaluation, as do the incentives surrounding the delivery of these interventions in ambulatory intervention suites.
尽管社会指南指出外周血管介入(PVI)不应作为间歇性跛行的一线治疗方法,但仍有相当数量的患者在确诊后 6 个月内接受 PVI 治疗跛行。本研究旨在探讨跛行早期 PVI 与后续干预的关系。
我们评估了 Medicare 按服务收费的 100%索赔,以确定从 2015 年 1 月 1 日至 2017 年 12 月 31 日期间有新诊断为跛行的所有受益人的信息。主要结局是晚期干预,定义为跛行诊断后>6 个月进行的任何股腘 PVI(截至 2021 年 6 月 30 日)。Kaplan-Meier 曲线用于比较跛行患者早期(≤6 个月)PVI 与无早期 PVI 患者的晚期 PVI 累积发生率。分层 Cox 比例风险模型用于评估与晚期 PVI 相关的患者和医生特征。
在研究期间,共有 187442 名患者有新的跛行诊断,其中 6069 名(3.2%)接受了早期 PVI。中位随访 4.39 年(四分位距 3.62-5.17 年)后,22.5%的早期 PVI 患者接受了晚期 PVI,而无早期 PVI 的患者为 3.6%(P<0.001)。接受早期 PVI 高使用率医生(≥2 个标准差;医生异常值)治疗的患者比接受标准使用率医生治疗的患者更有可能接受晚期 PVI(9.8%比 3.9%;P<0.001)。接受早期 PVI(16.4%比 7.8%)和接受异常值医生治疗的患者(9.7%比 8.0%)更有可能发展为 CLI(两者均 P<0.001)。调整后,与晚期 PVI 相关的患者因素包括接受早期 PVI(调整后的危险比[HR],6.89;95%置信区间[CI],6.42-7.40)和黑种人(与白种人相比;HR,1.19;95%CI,1.10-1.30)。与晚期 PVI 唯一相关的医生因素是大部分手术在门诊手术中心或基于办公室的实验室进行,门诊手术中心或基于办公室的实验室服务比例增加与晚期 PVI 发生率显著增加相关(四分位 4 比四分位 1;HR,1.57;95%CI,1.41-1.75)。
与早期非手术治疗相比,跛行诊断后早期 PVI 与更高的晚期 PVI 率相关。跛行早期 PVI 的高使用率医生比他们的同行进行了更多的晚期 PVI,尤其是那些主要在高补偿环境中提供护理的医生。早期 PVI 治疗跛行的适宜性需要进行严格评估,围绕这些干预措施在门诊介入室的实施的激励措施也是如此。